Resultados da pesquisa - Iris M. Seignette
- A mostrar 1 - 1 resultados de 1
-
1
Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma Por Joris L. Vos, Joris B.W. Elbers, Oscar Krijgsman, Joleen J.H. Traets, Xiaohang Qiao, Anne M. van der Leun, Yoni Lubeck, Iris M. Seignette, Laura A. Smit, Stefan M. Willems, Michiel W. M. van den Brekel, Richard Dirven, Barış Karakullukçu, L.H.E. Karssemakers, W. Martin C. Klop, Peter J. F. M. Lohuis, Willem H. Schreuder, Ludi E. Smeele, Lilly‐Ann van der Velden, I. Bing Tan, Suzanne Onderwater, Bas Jasperse, Wouter V. Vogel, Abrahim Al‐Mamgani, Astrid Keijser, Vincent van der Noort, Annegien Broeks, Erik Hooijberg, Daniel S. Peeper, Ton N. Schumacher, Christian U. Blank, Jan Paul de Boer, John B.A.G. Haanen, Charlotte L. Zuur
Publicado em 2021Artigo
Ferramentas de pesquisa:
Assuntos relacionados
Biopsy
Cancer
Carcinoma
Clinical endpoint
Clinical trial
Head and neck cancer
Head and neck squamous-cell carcinoma
Immune checkpoint
Immunotherapy
Internal medicine
Ipilimumab
Medicine
Metastasis
Nivolumab
Oncology
Pathological
Phases of clinical research
Primary tumor
Response Evaluation Criteria in Solid Tumors